Logo Image

Shorts

Adverse Events to Watch for With Ribociclib
0:30
Adverse Events to Watch for With Ribociclib
a year ago
by
Sara A. Hurvitz, MD
Dr Mayer Discusses PFS Data From evERA at ESMO 2025
0:45
Dr Mayer Discusses PFS Data From evERA at ESMO 2025
a year ago
by
Erika Mayer, MD, MPH
How a New Drug is Changing Breast Cancer Treatment Forever
0:19
How a New Drug is Changing Breast Cancer Treatment Forever
a year ago
by
Joyce A. O’Shaughnessy, MD
1 in 3 Breast Cancer Patients at High Risk
0:21
1 in 3 Breast Cancer Patients at High Risk
a year ago
by
Joyce A. O’Shaughnessy, MD
Why Understanding Tumor Biology is Key to Better Breast Cancer Care
0:37
Why Understanding Tumor Biology is Key to Better Breast Cancer Care
a year ago
by
Sarah Premji, MD
FDA Requires 5 Years of Follow Up—Is It Too Much?
0:37
FDA Requires 5 Years of Follow Up—Is It Too Much?
a year ago
by
Harpreet Singh, MD
How Breast Cancer Treatment Became More Personalized & Effective
0:20
How Breast Cancer Treatment Became More Personalized & Effective
a year ago
by
Sarah Premji, MD
Reviewing the FDA Draft Guidance on Radiopharmaceuticals
0:17
Reviewing the FDA Draft Guidance on Radiopharmaceuticals
a year ago
by
Harpreet Singh, MD
Advantages of NK Cell Therapy
0:37
Advantages of NK Cell Therapy
a year ago
by
Katy Rezvani, MD, PhD
Understanding High-Risk Smoldering Multiple Myeloma
0:21
Understanding High-Risk Smoldering Multiple Myeloma
a year ago
by
Paula Rodriguez Otero, MD, PhD
Looking Ahead From DeLLphi-303
0:28
Looking Ahead From DeLLphi-303
a year ago
by
Kelly Paulson, MD, PhD
Dr Petrylak: Unmet Needs in Prostate Cancer
0:31
Dr Petrylak: Unmet Needs in Prostate Cancer
a year ago
by
Daniel P. Petrylak, MD
Blood Cancer Awareness Month: Unmet Needs in Lymphoma
0:29
Blood Cancer Awareness Month: Unmet Needs in Lymphoma
a year ago
by
Andrew Jallouk, MD, PhD
Dr Poh: Considerations for Tafasitamab
0:19
Dr Poh: Considerations for Tafasitamab
a year ago
by
Christina Poh, MD
Vepdegestrant for ESR1-Mutant Breast Cancer: Safety and Tolerability
0:21
Vepdegestrant for ESR1-Mutant Breast Cancer: Safety and Tolerability
a year ago
by
Erika P. Hamilton, MD
Funding Cancer Research
0:24
Funding Cancer Research
a year ago
by
Robert L. Ferris, MD, PhD
A New Hope: Fighting Ovarian Cancer at its Weakest
1:01
A New Hope: Fighting Ovarian Cancer at its Weakest
a year ago
by
Amir Jazaeri, MD
Talquetamab: The Perfect Bridge to CAR T?
1:00
Talquetamab: The Perfect Bridge to CAR T?
a year ago
by
Binod Dhakal, MD, MS
The Race Against Time: Why CAR T-Cell Therapy Isn't a Quick Fix
1:10
The Race Against Time: Why CAR T-Cell Therapy Isn't a Quick Fix
a year ago
by
Binod Dhakal, MD, MS
Clinical Trial Limitations in MDS
0:18
Clinical Trial Limitations in MDS
a year ago
by
Guillermo Garcia-Manero, MD
Impactful Survival Data from the COMMANDS Trial of Luspatercept in Low-Risk MDS
0:17
Impactful Survival Data from the COMMANDS Trial of Luspatercept in Low-Risk MDS
a year ago
by
Guillermo Garcia-Manero, MD
Dr Wen: Treatment Considerations for Dordaviprone in Diffuse Midline Glioma
0:31
Dr Wen: Treatment Considerations for Dordaviprone in Diffuse Midline Glioma
a year ago
by
Patrick Wen, MD